CR Double-Crane Pharma Gets Registration Certificate for Oxcarbazepine Tablets

MT Newswires Live

Yesterday

China Resources Double-Crane Pharmaceutical (SHA:600062) received a drug registration certificate from the National Medical Products Administration for its oxcarbazepine tablets, according to a Shanghai bourse filing on Tuesday.

The certificate was received through subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan).

The drug is used as treatment for primary generalized tonic-clonic seizures and partial seizures, with or without secondary generalized seizures, for children and adults.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/2664839144"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664839144\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664839144?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 15:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664839144","market":"hk","top_or_hot":-1,"title":"CR Double-Crane Pharma Gets Registration Certificate for Oxcarbazepine Tablets","media":"MT Newswires Live","content":"<html><body><p> China Resources Double-Crane Pharmaceutical (SHA:600062) received a drug registration certificate from the National Medical Products Administration for its oxcarbazepine tablets, according to a Shanghai bourse filing on Tuesday.</p><p>The certificate was received through subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan).</p><p>The drug is used as treatment for primary generalized tonic-clonic seizures and partial seizures, with or without secondary generalized seizures, for children and adults.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Double-Crane Pharma Gets Registration Certificate for Oxcarbazepine Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Double-Crane Pharma Gets Registration Certificate for Oxcarbazepine Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-01 15:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China Resources Double-Crane Pharmaceutical (SHA:600062) received a drug registration certificate from the National Medical Products Administration for its oxcarbazepine tablets, according to a Shanghai bourse filing on Tuesday.</p><p>The certificate was received through subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan).</p><p>The drug is used as treatment for primary generalized tonic-clonic seizures and partial seizures, with or without secondary generalized seizures, for children and adults.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CR","symbol_name":"crane","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664839144","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664839144","pubTimestamp":1788247666,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China Resources Double-Crane Pharmaceutical  received a drug registration certificate from the National Medical Products Administration for its oxcarbazepine tablets, according to a Shanghai bourse filing on Tuesday.The certificate was received through subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical .The drug is used as treatment for primary generalized tonic-clonic seizures and partial seizures, with or without secondary generalized seizures, for children and adults.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600062":"华润双鹤","CR":"crane","BK0010":"央企","BK0239":"医药制造","BK0028":"国家队","BK0185":"二线龙头","BK0188":"融资融券","BK0175":"白马股"},"translate_title":"华润双鹤药业获得奥卡西平片注册证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":0.9,"CR":1.5},"content_text":"China Resources Double-Crane Pharmaceutical (SHA:600062) received a drug registration certificate from the National Medical Products Administration for its oxcarbazepine tablets, according to a Shanghai bourse filing on Tuesday.The certificate was received through subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan).The drug is used as treatment for primary generalized tonic-clonic seizures and partial seizures, with or without secondary generalized seizures, for children and adults.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}